Market Capitalization (Millions $) |
0 |
Shares
Outstanding (Millions) |
119 |
Employees |
34 |
Revenues (TTM) (Millions $) |
2 |
Net Income (TTM) (Millions $) |
-54 |
Cash Flow (TTM) (Millions $) |
-66 |
Capital Exp. (TTM) (Millions $) |
0 |
Humanigen Inc
Humanigen Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for patients with serious and life-threatening diseases. The company is dedicated to advancing its proprietary monoclonal antibody platform to create transformative treatments for various conditions, including infectious diseases and cancer. Humanigen's lead product candidate, lenzilumab, is being evaluated for its potential efficacy in treating cytokine storm, a severe immune response that can lead to respiratory failure, particularly in COVID-19 patients. Humanigen Inc. aims to leverage its scientific expertise and partnerships to make meaningful contributions to the field of healthcare and improve patient outcomes.
Company Address: 830 Morris Turnpike Short Hills 7078 NJ
Company Phone Number: 200-3100 Stock Exchange / Ticker: NASDAQ HGEN
|